RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Cause, conseguenze, e aspetti terapeutici dell'iperomocisteinemia nell'uremia e nel diabete.
• 2 - Ruolo di citochine ed ormoni di origine gastrointestinale ed adipocitaria nella patogenesi dell'obesità e delle sue complicanze
• 3 - Studio dei meccanismi molecolari alla base dell’anomala proliferazione e funzione paratiroidea, e identificazione ed uso clinico di marcatori molecolari di carcinoma paratiroideo sporadico e familiare. Nuove acquisizione sulla prevalenza delle manifestazioni scheletriche, neuropsichiche e metaboliche dell’iperparatiroidismo primario, loro relazione con i polimorfismi del recettore del calcio ed effetti della paratiroidectomia.
• 4 - EFFETTI DEGLI INIBITORI DELLA FOSFODIESTERASI TIPO 5 (PDE5i) SULLA FUNZIONE SESSUALE, ENDOCRINA E VASCOLARE
• 5 - Fisiopatologia,clinica e terapia dei tumori corticosurrenalici
• 6 - Studio degli effetti genomici dell'aldosterone in modelli cellulari ed in vivo.
• 7 - RUOLO DEI MECCANISMI DI SEGNALE CELLULARE E DELLE SPECIE REATTIVE DELL'OSSIGENO E DELL'AZOTO NELL'INVECCHIAMENTO CELLULARE E NELLA CRESCITA NEOPLASTICA.
• 8 - PRODUZIONE E CATABOLISMO DELLA BETA-AMILOIDE IN PAZIENTI CON MALATTIA DI ALZHEIMER E MILD COGNITIVE IMPAIRMENT: STUDI IN VITRO E MARKERS EX VIVO
• 9 - L'antiangiogenesi nella sclerosi sistemica:studio delle alterazioni dei meccanismi fibrinolitici e neoangeogenetici attraverso l'utilizzo di tecniche proteomiche e genomiche applicate a leucociti, fibroblasti e cellule endoteliali
• 10 - Meccanismi di controllo dell’eritropoiesi e policitemie congenite e familiari: ruolo delle vie di risposta alla pressione di ossigeno

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • MEDICINA INTERNA
  • MALATTIE DELL'APPARATO CARDIOVASCOLARE
  • ENDOCRINOLOGIA
  • MALATTIE DEL SANGUE
  • REUMATOLOGIA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Marche

Bibliografia

Coagulazione e danno aterosclerotico
1. Patrassi GM, Sartori MT, Viero ML, Scarano L, Boscaro M, Girolami A. The fibrinolytic potential in patients with Cushing’s disease : a clue to their hypercoagulable state. Blood Coag Fibrinol 1992: 3: 789-93.
2. Patrassi GM, Sartori MT, Livi U, Casonato A, Danesin C, Vettore S, Girolami A. Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation. Transplantation 1997: 64: 1610-14.
4.Dal Bo Zanon R, Fornasiero L, Boscaro M, Cappellato G, Fabris F, Girolami A. Increased factor VIII associated activities in Cushing’s syndrome: a probable hypercoagulable state. Thromb Haemost 1982; 47: 116-7.
5. Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM, Girolami A. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s sindrome. J Clin Endocrinol Metabol 2002; 87: 3662-6.
6. Casonato A, Pontara E, Boscaro M, Sonino N, Sartorello F, Ferrasin S, Girolami A. Abnormalities of von Willebrand factor are also part of the thrombotic state of Cushing’s syndrome. Blood Coag. Fibrinol, 10:145-151, 1999
7. Denis CV. Von Willebrand factor in vascular pathophysiology. Pathologie Biologie 51: 395-396, 2003.
11. Sadler J.E. Biochemistry and genetics of von Willebrand disease. Annu. Rev. Biochem. 67, 395-424, 1998
14. Van Zonneveld AJ, Curriden SA, Loskutoff DJ. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci USA 1988; 85: 5525-29.
16. Sartori M.T., Vettor R., De Pergola G., De Mitro V., Saggiorato G., Della Mea P., Patrassi G.M., Lombardi A.M., Fabris R., Girolami A. Role of the 4G/5G polymorphism of PAI-1 gene promoter on PAI-1 levels in obese patients: influence of fat distribution and insulin-resistance. Thromb Haemost 2001; 86; 1161-9.
17. Sartori MT, Wiman B, Vettore S, Dazzi F, Girolami A, Patrassi GM. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost 1998; 80: 956-60.
Tessuto adiposo
1. Bjorntorp P,Rosmond R. 2000. The metabolic syndrome – a neuroendocrine disorder? Br J Nutr 83:S49-S57.
2. Rebuffe-Scrive M, Krotkiewski M, Elfverson J, Bjorntorp P. 1988. Muscle and adipose tissue morphology and metabolism in Cusing syndrome. J Clin Endocrinol Metab 67:1122-1128.
3. Bujalska IJ, Kumar S, Stewart PM. 1997. Does central obesity reflect “Cushing’s disease of the omentum”? Lancet 349:1210-12132.
4 Cinti S, Cigolini M, Bosello O, Bjorntorp P. 1984. A morphological study of the adipocyte precursor. J Submicrosc Cytol 16(2):243-251,
5. Cinti S. 1999. The adipose organ. Kurtis Milano Ital
6. Hauner H, Enterman G, Wabitsch M, Gaillard D, Aihlhaud G, Negrel R, Pfeiffer EF. 1989. Promoting effects of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest 84:1663-1670
7. Bujalska IJ, Walker EA, Hewison M, Stewart PM. 2002. A switch in dehydrogenase to reductase activity of 11b-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromali cells. J Clin Endocrinol Metab 87:1205-1210.
8. Rebuffe-Scrive M, Krotkiewski M, Elfverson J, Bjorntorp P. 1988. Muscle and adipose tissue morphology and metabolism in Cusing syndrome. J Clin Endocrinol Metab 67:1122-1128.
9. Livingstone DEW, Jones GC, Smith K, Jamieson PM, Andrew R, Kenyon CJ, Walzer BR. 2000. Understanding thre role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 141:560-563.
10. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. 2001. A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170.
11. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi M-C, Grino M. 2002. Expression of the mRNA coding for 11b-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridisation study. J Clin Endocrinol Metab 87(6):2701-2705.
Osso
2. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
4. Canalis E. Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996;81:3441-7.
5. Angeli A, Osella G, Reimondo G, Terzolo M. Glucocorticoid-induced osteoporosis: recent findings. Ann Ital Med Int 2000;15:47-55
7. Pereira RM, Delany AM, Canalis E. Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 2001;28:484-90..
8. Aubin JE. Regulation of osteoblast formation and function. Rev Endocr Metab Disord 2001;2:81-94.
9. Dovio A, Masera RG, Sartori ML, Racca S, Angeli A. Autocrine up-regulation of GC receptors by IL-6 in human osteoblast-like cells. Calcif Tissue Int
10. Rakasz E, Gal A, Biro J, Balas G, Falus A. Modulation of glucocorticosteroid binding in human lymphoid, monocytoid and hepatoma cell lines by inflammatory cytokines interleukin (IL)-1 beta, IL-6 and tumour necrosis factor (TNF)-alpha. Scand J Immunol 1993;37:684-9.
11. Bu R, Borysenko CW, Li Y, Cao L, Sabokbar A, Blair HC. Expression and function of TNF-family proteins and receptors in human osteoblasts. Bone.2003;33(5):760-70.
12. Tsuboi M, Kawakami A, Nakashima T, Matsuoka N, Urayama S, Kawabe Y, Fujiyama K, Kiriyama T, Aoyagi T, Maeda K, Eguchi K. Tumor necrosis factor-alpha and interleukin-1beta increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med.1999; 134(3):222-31.
13. Kawakami A, Eguchi K, Matsuoka N, Tsuboi M, Koji T, Urayama S, Fujiyama K, Kiriyama T, Nakashima T, Nakane PK, Nagataki S. Fas and Fas ligand interaction is necessary for human osteoblast apoptosis. J Bone Miner Res.1997; 12(10):1637-46. .
18. Vottero A, Chrousos GP. Glucocorticoid Receptor beta: View I. Trends Endocrinol Metab 1999;10:333-338.
19. Beavan S, Horner A, Bord S, Ireland D, Compston J. Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. J Bone Miner Res 2001;16:1496-504.
Muscolo
1. Allsop KG, Ziter FA. Loss of strength and functional decline in Duchenne Dystrophy. Arch Neurol 1981;38:406-411.
2. Dubowitz V. The Muscular dystrophies In: Dubowitz V, editor. Muscle Disorders in Childhood. London, Philadelphia and Toronto: Saunders; 1995. p 38-48.
3.Engel AG, Yamamoto M, Fischbeck KH. Muscular dystrophies In: Engel AG, Franzini-Armstrong C, editors. Myology. New York: McGraw Hill; 1994. p 1133–1187.
Burrow KL, Coovert DD, Klein CJ, Bulman DE, Kissel JT, Rammohan KW, Burghes AHM, 4.Mendell JR, and the CIDD group. Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. Neurology 1991;41:661-666.
5. Kissel JT, Burrow KL, Rammohan KW, Mendell JR and the CIDD. Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. Neurology 1991;41:667-672.
GC receptors
2. Rosmond, R. The glucocorticoid receptor gene and its association to metabolic syndrome. Obes Res. 2002; 10:1078 –1086
8. Dobson MG, Redfern CP, Unwin N, Weaver JU. The N363S polymorphism of the glucocorticoid receptor: potential contribution to central obesity in men and lack of association with other risk factors for coronary heart disease and diabetes mellitus. J Clin Endocrinol Metab. 2001;86:2270–4
10. Rosmond R, Chagnon YC, Holm G, et al. A glucocorticoid receptor gene marker is associated with abdominal obesity, leptin, and dysregulation of the hypothalamic-pituitary-adrenal axis. Obes Res. 2000;8:211–8.
12. S.W.J. Lamberts. Glucocorticoid receptors and Cushing’s disease Molecular and Cellular Endocrinology 197 (2002) 69-72
17. Lin RC, Wang XL, Morris BJ. Association of Coronary Artery Disease With Glucocorticoid Receptor N363S Variant. Hypertension 2003 Mar;41(3):404-7

Parole Chiave

GLUCOCORTICOIDI; RECETTORI DEI GLUCOCORTICOIDI; SINDROME DI CUSHING; OSTEOPOROSI INDOTTA DAI GLUCOCORTICOIDI; DISTROFIA MUSCOLARE; OBESITÀ; FIBRINOLISI; RISCHIO CARDIOVASCOLARE; 11 BETA HSD